ClinicalTrials.gg
CompletedNCT00595517Updated Sep 14, 2012Results posted

Long Term Study to Investigate the Efficacy & Safety of D961H (Esomeprazole) for the Prevention of NSAIDs-induced Ulcer

A Phase 3 interventional study of Esomeprazole 20 mg in Gastric Ulcer, Duodenal Ulcer and Rheumatoid Arthritis, sponsored by AstraZeneca. Completed at 3 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2012-09-14.

Sponsored by AstraZeneca · Phase 3, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
395
Allocation
Non-randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 11 studies testing esomeprazole in Stomach Ulcer — none open to participants now, none under way, none of them phase 3. Esomeprazole · Stomach Ulcer.

Enrollment
8th of 11
395 · median 400
Started
2007
with 2 others
Phase 3
9 of 11
none open now
Registered
5th of 11
by date
Lead sponsor
10 of 11
AstraZeneca

Among the 11 studies testing esomeprazole in Stomach Ulcer, this one is the 8th largest by enrollment, is one of 3 that started in 2007, is one of 9 in phase 3, and was the 5th registered.

Stomach Ulcer

116 studies on the registry are indexed under Stomach Ulcer; 13 are open to participants now.

Browse Stomach Ulcer studies →

Open to participants now

None of the 11 studies testing esomeprazole in Stomach Ulcer is open now. The open studies under Stomach Ulcer, anywhere →

About esomeprazole

Esomeprazole: first FDA approval 2001 (NEXIUM), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 10 Stomach Ulcer studies recruiting now, 6 (60%) set no upper age limit and 3 (30%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies testing esomeprazole in Stomach Ulcer as a file.
02

Study summary

The purpose of this study is to assess the Safety and tolerability of D961H (Esomeprazole) 20 mg once daily for up to 52 weeks of treatment involving patients with a history of gastric and/or duodenal ulcers receiving daily nonsteroidal anti-inflammatory drug (NSAID) therapy by evaluating AE, clinical laboratory value and vital signs.

03

Conditions studied

  • Gastric Ulcer
  • Duodenal Ulcer
  • Rheumatoid Arthritis
  • Osteoarthritis
  • Lumbago

Keywords

  • gastrointestinal
  • GI
  • NSAID
  • Japan
  • Japanese
  • Gastric ulcer
  • duodenal ulcer
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Medical history of gastric and/or duodenal ulcer
  • A diagnosis of a chronic condition (rheumatoid arthritis, osteoarthritis, lumbago,etc) that requires daily NSAID use,at least 20 years of age

Exclusion criteria

Exclusion Criteria:

  • Having gastric or duodenal ulcer in active or healing stage according to the Sakita/Miwa classification
  • History of esophageal, gastric or duodenal surgery
  • Having severe liver disease or chronic renal disease
05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
395 participants (actual)

Study arms

  • Experimental
    Esomeprazole 20 mg

    Esomeprazole 20 mg once daily

    Drug: Esomeprazole 20 mg

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants Without Gastric and/or Duodenal Ulcer Throughout the Treatment Period

    Time frame: up to 52 weeks

Secondary outcomes

  1. Number of Participants Without Gastric and/or Duodenal Ulcer up to 4 Weeks After Treatment

    Time frame: up to 4 weeks after treatment

  2. Number of Participants Without Gastric and/or Duodenal Ulcer up to 12 Weeks After Treatment

    Time frame: up to 12 weeks after treatment

  3. Number of Participants Without Gastric and/or Duodenal Ulcer up to 24 Weeks After Treatment

    Time frame: up to 24 weeks after treatment

07

Results

Posted Sep 14, 2012

Participant flow

First participant enrolled 2 Oct 07. Last completed 8 Sept 09. 395 enrolled, 130 registered in study. All registered were included in Full Analysis set and safety analysis set. FAS used for summaries of baseline characteristics and efficacy, safety analysis set for summaries of safety variables.

Participant flow — Overall Study
MilestoneEsomeprazole 20mg
Started130
Completed111
Not completed19
Withdrew: Adverse event6
Withdrew: Withdrawal by subject4
Withdrew: Protocol violation2
Withdrew: Recurrence of ulcer5
Withdrew: Usage of prohibited treatment1
Withdrew: No intention to attend regularly1

Outcome measures

SecondaryNumber of Participants Without Gastric and/or Duodenal Ulcer up to 4 Weeks After Treatment
Time frame:
up to 4 weeks after treatment
Reported as:
Number · Participants
Number of Participants Without Gastric and/or Duodenal Ulcer up to 4 Weeks After Treatment
ParticipantsEsomeprazole 20mg
Number of Participants Without Gastric and/or Duodenal Ulcer up to 4 Weeks After Treatment130 (NA to NA)
SecondaryNumber of Participants Without Gastric and/or Duodenal Ulcer up to 12 Weeks After Treatment
Time frame:
up to 12 weeks after treatment
Reported as:
Number · participants
Number of Participants Without Gastric and/or Duodenal Ulcer up to 12 Weeks After Treatment
participantsEsomeprazole 20mg
Number of Participants Without Gastric and/or Duodenal Ulcer up to 12 Weeks After Treatment127 (NA to NA)
SecondaryNumber of Participants Without Gastric and/or Duodenal Ulcer up to 24 Weeks After Treatment
Time frame:
up to 24 weeks after treatment
Reported as:
Number · participants
Number of Participants Without Gastric and/or Duodenal Ulcer up to 24 Weeks After Treatment
participantsEsomeprazole 20mg
Number of Participants Without Gastric and/or Duodenal Ulcer up to 24 Weeks After Treatment126 (NA to NA)
PrimaryNumber of Participants Without Gastric and/or Duodenal Ulcer Throughout the Treatment Period
Time frame:
up to 52 weeks
Reported as:
Number · Participants
Number of Participants Without Gastric and/or Duodenal Ulcer Throughout the Treatment Period
ParticipantsEsomeprazole 20mg
Number of Participants Without Gastric and/or Duodenal Ulcer Throughout the Treatment Period125

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Esomeprazole 20mg—14/130 (10.8%)123/130 (94.6%)
Most frequent serious events
Showing 10 of 14
Most frequent serious events
EventEsomeprazole 20mg
Rheumatoid Arthritis AggravatedMusculoskeletal and connective tissue disorders3/130
Osteoarthritis DeteriorationMusculoskeletal and connective tissue disorders2/130
PyelonephritisInfections and infestations2/130
Pain In ExtremityMusculoskeletal and connective tissue disorders1/130
SpondylolisthesisMusculoskeletal and connective tissue disorders1/130
ErysipelasInfections and infestations1/130
InfluenzaInfections and infestations1/130
PneumoniaInfections and infestations1/130
SepsisInfections and infestations1/130
Campylobacter Intestinal InfectionInfections and infestations1/130
Most frequent other events
Showing 10 of 15
Most frequent other events
EventEsomeprazole 20mg
NasopharyngitisInfections and infestations38/130
Rheumatoid ArthritisMusculoskeletal and connective tissue disorders17/130
Abdominal Pain UpperGastrointestinal disorders14/130
ConstipationGastrointestinal disorders12/130
DiarrhoeaGastrointestinal disorders11/130
Stomach DiscomfortGastrointestinal disorders10/130
OsteoarthritisMusculoskeletal and connective tissue disorders9/130
NauseaGastrointestinal disorders8/130
HeadacheNervous system disorders8/130
StomatitisGastrointestinal disorders7/130

Baseline characteristics

Age, Customized
Age, Customized(Participants)Esomeprazole 20mg
< 65 years63 (63 to NA)
65 - 74 years43 (43 to NA)
>= 75 years24 (24 to NA)
Sex/Gender, Customized
Sex/Gender, Customized(Participants)Esomeprazole 20mg
Male35 (35 to NA)
Female95 (95 to NA)
08

Study locations

3 sites
  • Research Site
    Oita, Japan
  • Research Site
    Saitama, Japan
  • Research Site
    Tokyo, Japan
09

References and documents

Publications

  • Sugano K, Kinoshita Y, Miwa H, Takeuchi T; Esomeprazole NSAID Preventive Study Group. Safety and efficacy of long-term esomeprazole 20 mg in Japanese patients with a history of peptic ulcer receiving daily non-steroidal anti-inflammatory drugs. BMC Gastroenterol. 2013 Mar 26;13:54. doi: 10.1186/1471-230X-13-54. PubMed 23530709 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2007, a primary completion of Sep 2009 and a completion of Sep 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2012, 3 years after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 7, 2008
First posted
Jan 16, 2008
Start
Oct 2007
Primary completionActual
Sep 2009
CompletionActual
Sep 2009
Results first posted
Sep 14, 2012
Last update
Sep 14, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 14, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00595517
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Jan 16, 2008
Start date
Oct 2007
Primary completion
Sep 2009
Completion
Sep 2009
Results posted
Sep 14, 2012
Last update
Sep 14, 2012

Study contacts

Naotsugu Oyama
study director · AstraZeneca

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Esomeprazole

Start the discussion